‘Forget forecasts – focus on quality’, says Claremont Global chief Bob Desmond

Bob Desmond is making his first appearance at the 2022 Sohn Hearts & Minds Conference.

Glenda Korporaal

‘Forget forecasts – focus on quality’, says Claremont Global chief Bob Desmond

October 24, 2022
Bob Desmond is making his first appearance at the 2022 Sohn Hearts & Minds Conference.
Read Transcript

Claremont Global head Bob Desmond says he learnt the importance of investing in quality companies when growing up in Zimbabwe during a time of hyperinflation.

“What I learned from that is no matter how bad economies get – and things got really bad in Zimbabwe – high-quality businesses which have high margins, strong balance sheets, strong cash flows and are capital-light can be very resilient,” he said in an interview with The Australian.

“I grew up in a world which was very uncertain, so I don’t try to predict the future."

“I just try to buy the highest-quality businesses. So, no matter what happens, you can protect capital for your clients.”

Desmond, who worked in London before moving to Australia in 2008, is making his first appearance at the annual Sohn Hearts & Minds Investment Leaders Conference, where fund managers give their favourite stock tips to raise money for medical research charities. The conference, which is now back to being held in person, will be in Hobart for the first time on Friday November 18.

Desmond oversees Claremont Global, a $1.2bn international investment fund which focuses its investment on 14 global companies, including LVMH, Nike, Visa, Alphabet, Microsoft, Adobe, Equifax and CME.

Desmond says he will recommend the one which is best priced at the time.

“We’ve got a small number of stocks which are all global leaders in their industry,” he says.

“They have higher than average revenue growth, higher than average margins, strong balance sheets and cash flow, good capital allocation by management and an understanding of their competitive advantage.”

The fund deliberately excludes investments in banks as well as companies in insurance, resources, oil and pharmaceuticals.

Desmond says his approach to investing is to not try to predict economic and market cycles.

He believes investors should give up pretending that they know what is going to happen to economies and look at the underlying quality of companies.

“I don’t know anyone who told me that the Fed would be as aggressive as it has been on rates this year,” he said.

“No one told me that there would be a pandemic and that governments would respond with a big amount of fiscal and monetary stimulus.”

Australian investors, he points out, would also have been misled had they banked on the comments by the Reserve Bank that it was not expecting to raise interest rates until 2024.

“The future is inherently unknowable,” he says.

Claremont, he explains, looks for companies with growth opportunities, and never buys a stock just because it is cheap.

Desmond likes high-quality companies as they can ride out economic cycles.

Luxury brand company LVMH, which owns a range of global brands including Christian Dior, Sephora, Moet & Chandon, Krug, Hennessy, Fendi, Givenchy and Bulgari, is growing strongly despite talk of recession.

While its sales in China are down, because of the downturn in its economy, the company is seeing strong growth in the US.

“It’s a really strong line-up of brands and amazing management which has been in place for more than 30 years,” Desmond says.

Visa, he says, is benefiting from the resumption of global travel.

Despite concerns about the prospects of a recession, Desmond says consumer spending is still holding up well globally.

He believes that good brands will outperform in a downturn.

One less well known company he holds is Zoetis, the world’s largest producer of medicine and vaccines for animals and livestock, which was spun off from Pfizer.

Desmond sees the company’s growth driven by increasing spending on pet care.

Claremont has a global watch list of about 120 stocks, with an approved list of about 40.

Unlike some other funds focused on international investing, such as Platinum Asset Management and Magellan, Claremont has avoided any investment in Chinese stocks.

Desmond says he looked at investing in e-commerce giant Alibaba but decided against it because of the uncertainty over shareholder protection for Chinese stocks.

Most of Claremont’s stocks are based in the US, a market where he says there are still good global companies that are undervalued compared to their peers in Australia and Europe.

Desmond says another lesson he has learned in his investing career is to “try and be more of an optimist” when it comes to the sharemarket.

“I’ve always been on the bearish side of life,” he says.

“The Asian crisis was pretty scary, the dot.com crisis was scary, the Global Financial Crisis was petrifying. And then we had Brexit and Trump and Covid-19.

“These events have all happened. But what has come out, over time, is that if you buy good businesses, their earnings are growing and you take a long-term view, you are going to get a good return from your investments.”

The Sohn Hearts & Minds Investment Leaders Conference is an annual one-day event which brings the investment community together in support of Australian medical research.

It was held on Friday 18 November, Sohn Hearts & Minds in Hobart, with support from the Tasmanian government.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Claremont Global head Bob Desmond says he learnt the importance of investing in quality companies when growing up in Zimbabwe during a time of hyperinflation.

“What I learned from that is no matter how bad economies get – and things got really bad in Zimbabwe – high-quality businesses which have high margins, strong balance sheets, strong cash flows and are capital-light can be very resilient,” he said in an interview with The Australian.

“I grew up in a world which was very uncertain, so I don’t try to predict the future."

“I just try to buy the highest-quality businesses. So, no matter what happens, you can protect capital for your clients.”

Desmond, who worked in London before moving to Australia in 2008, is making his first appearance at the annual Sohn Hearts & Minds Investment Leaders Conference, where fund managers give their favourite stock tips to raise money for medical research charities. The conference, which is now back to being held in person, will be in Hobart for the first time on Friday November 18.

Desmond oversees Claremont Global, a $1.2bn international investment fund which focuses its investment on 14 global companies, including LVMH, Nike, Visa, Alphabet, Microsoft, Adobe, Equifax and CME.

Desmond says he will recommend the one which is best priced at the time.

“We’ve got a small number of stocks which are all global leaders in their industry,” he says.

“They have higher than average revenue growth, higher than average margins, strong balance sheets and cash flow, good capital allocation by management and an understanding of their competitive advantage.”

The fund deliberately excludes investments in banks as well as companies in insurance, resources, oil and pharmaceuticals.

Desmond says his approach to investing is to not try to predict economic and market cycles.

He believes investors should give up pretending that they know what is going to happen to economies and look at the underlying quality of companies.

“I don’t know anyone who told me that the Fed would be as aggressive as it has been on rates this year,” he said.

“No one told me that there would be a pandemic and that governments would respond with a big amount of fiscal and monetary stimulus.”

Australian investors, he points out, would also have been misled had they banked on the comments by the Reserve Bank that it was not expecting to raise interest rates until 2024.

“The future is inherently unknowable,” he says.

Claremont, he explains, looks for companies with growth opportunities, and never buys a stock just because it is cheap.

Desmond likes high-quality companies as they can ride out economic cycles.

Luxury brand company LVMH, which owns a range of global brands including Christian Dior, Sephora, Moet & Chandon, Krug, Hennessy, Fendi, Givenchy and Bulgari, is growing strongly despite talk of recession.

While its sales in China are down, because of the downturn in its economy, the company is seeing strong growth in the US.

“It’s a really strong line-up of brands and amazing management which has been in place for more than 30 years,” Desmond says.

Visa, he says, is benefiting from the resumption of global travel.

Despite concerns about the prospects of a recession, Desmond says consumer spending is still holding up well globally.

He believes that good brands will outperform in a downturn.

One less well known company he holds is Zoetis, the world’s largest producer of medicine and vaccines for animals and livestock, which was spun off from Pfizer.

Desmond sees the company’s growth driven by increasing spending on pet care.

Claremont has a global watch list of about 120 stocks, with an approved list of about 40.

Unlike some other funds focused on international investing, such as Platinum Asset Management and Magellan, Claremont has avoided any investment in Chinese stocks.

Desmond says he looked at investing in e-commerce giant Alibaba but decided against it because of the uncertainty over shareholder protection for Chinese stocks.

Most of Claremont’s stocks are based in the US, a market where he says there are still good global companies that are undervalued compared to their peers in Australia and Europe.

Desmond says another lesson he has learned in his investing career is to “try and be more of an optimist” when it comes to the sharemarket.

“I’ve always been on the bearish side of life,” he says.

“The Asian crisis was pretty scary, the dot.com crisis was scary, the Global Financial Crisis was petrifying. And then we had Brexit and Trump and Covid-19.

“These events have all happened. But what has come out, over time, is that if you buy good businesses, their earnings are growing and you take a long-term view, you are going to get a good return from your investments.”

The Sohn Hearts & Minds Investment Leaders Conference is an annual one-day event which brings the investment community together in support of Australian medical research.

It was held on Friday 18 November, Sohn Hearts & Minds in Hobart, with support from the Tasmanian government.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Oct 24, 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 14, 2022

Tim Carleton is backing the Aussie dream all the way

Carleton’s conviction will be on full display on Friday when he makes his third appearance at the Sohn Hearts & Minds Conference, where stock-pickers share their best ideas in the name of medical research.

Read More
November 10, 2022

Why this fundie is betting on luxury as recession fears mount

Bob Desmond is Head of Claremont Global and Co-Portfolio Manager. He will present at the Sohn Hearts & Minds Investment Leaders Conference in Tasmania on November 18.

Read More
November 7, 2022

This fundie couldn’t be happier with her portfolio

Joyce Meng is a presenter at this year’s Sohn Hearts & Minds Investment Leaders Conference on November 18, which takes place in Hobart and aims to raise money for medical research.

Read More
November 2, 2022

Equity Mates: Ricky Sandler, Eminence Capital

Founder, CIO and CEO of Eminence Capital Ricky Sandler talks about launching the $5.7bn asset manager, changing market structures and why he's participating in the SH&M conference.

Read More
November 1, 2022

Auscap Asset Management founder sticks to a winning formula

When Auscap Asset Management founder Tim Carleton tips a stock at the Sohn Hearts & Minds conference in Hobart, he doubts it will be a name that shocks investors.

Read More
October 31, 2022

Markets to enter ‘new phase’ with hidden risks lurking, says top stock picker Peter Cooper

One of Australia's most influential fund managers warns that investment markets have entered a “new phase” that is set to test the ­financial system.

Read More
October 31, 2022

Why Peter Cooper can’t wait for the next 30 years on markets

The veteran fund manager says the most uncertain period of his career will deliver huge opportunities – providing his firm can stick to its system.

Read More
October 30, 2022

Why this fundie is betting big on two losing companies

Speaking to the AFR before the SH&M conference, Sandler named global on-demand ride-sharing and food delivery service Uber Technologies among his top picks, alongside real estate marketplace Zillow.

Read More
October 27, 2022

Why this fundie is calling the peak for CBA shares

Jun Bei Liu is the lead Portfolio Manager at Tribeca Alpha Plus Fund and is set to present an investment idea at the Sohn Hearts & Minds Conference in Hobart on November 18.

Read More
October 24, 2022

Regal hedge fund manager says resources stocks are still cheap

Regal’s hedge fund focused on the resources space has thumped the market and its top stock picker, Tim Elliott, says resources stocks are still cheap.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.